Premium
4‐Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study
Author(s) -
Carella Angelo M.,
Santini Gino,
Martinengo Marina,
Giordano Domenico,
Nati Sandro,
Congiu Angela,
Cerri Raffaella,
Risso Marco,
Damasio Eugenio,
Rossi Edoardo,
Vimercati Renato,
Pacciarini Maria A.,
Marmont Alberto M.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850401)55:7<1452::aid-cncr2820550705>3.0.co;2-d
Subject(s) - idarubicin , medicine , amsacrine , refractory (planetary science) , cytarabine , leukemia , anthracycline , acute leukemia , gastroenterology , complete remission , chemotherapy , surgery , cancer , etoposide , physics , astrobiology , breast cancer
Twenty‐five adults with previously treated acute leukemia were treated with 4‐demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m 2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m‐Amsa (amsacrine), indicating a lack of cross‐resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.